8007
document
[ Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer -- the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin ] . A total of 465 patients with primary and multiple or recurrent , stages Ta and T1 superficial bladder cancer were included in this randomized multicenter trial to compare the prophylactic effect by 17 times instillation of 40 mg doxorubicin or 40 mg epirubicin with no instillation after transurethral resection of tumor ( s ) . The primary endpoint was first recurrence after transurethral resection . Endoscopic examination as well as urinary cytology was performed in each case every three months . It became evident that the recurrence rate in the doxorubicin or epirubicin instillation arm was lower that in the no instillation arm . Toxicity was mainly restricted to bladder irritation in about 10 % of patients in each instillation arm .
8008
Intervention_Pharmacological
doxorubicin
8009
Intervention_Pharmacological
40 mg doxorubicin
8010
Intervention_Physical
40 mg epirubicin
8011
Intervention_Pharmacological
doxorubicin
8012
Intervention_Pharmacological
epirubicin
8013
Outcome_Physical
first recurrence
8014
Outcome_Other
Endoscopic examination
8015
Outcome_Other
urinary cytology
8016
Outcome_Physical
recurrence rate
8017
Outcome_Adverse-effects
Toxicity
8018
Outcome_Adverse-effects
bladder irritation
8019
Participant_Sample-size
465
8020
Participant_Condition
superficial bladder cancer